Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

PAVM - PAVmed Inc. Latest News | Finranks

Home

/

PAVM

P

PAVmed Inc. (PAVM)

NCM – Real Time Price. Currency in USD

4.44

0.00 (0.00%)

Market open: Aug 12, 2026, 1:53 PM EDT

4.71

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteria NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer. Concert establishes coverage policies that its client health plans can adopt.

Lucid Diagnostics to Participate in Upcoming Investor Conferences

Lucid Diagnostics to Participate in Upcoming Investor Conferences

NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences: 11 th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 10, 2026 Location: Virtual Canaccord Genuity 46 th Annual Growth Conference Fireside Chat: August 11, 2026, at 11:30 AM ET Location: Boston, MA The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.

Videos

No Data

There is no data to display

Press releases

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteria NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer. Concert establishes coverage policies that its client health plans can adopt.